Metsera Inc
MTSR31.140USD
+0.840+2.77%
Close 08/15, 16:00（ET）Quotes delayed by 15 min
3.27BMarket Cap
LossP/E TTM
More Details of Metsera Inc Company
Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The Company's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
Company Info
Ticker SymbolMTSR
Company nameMetsera Inc
IPO dateJan 31, 2025
CEOMr. Christopher Whitten Bernard
Number of employees74
Security typeOrdinary Share
Fiscal year-endJan 31
Address3 World Trade Center
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10007
Phone12127846595
Websitehttps://metsera.com/
Ticker SymbolMTSR
IPO dateJan 31, 2025
CEOMr. Christopher Whitten Bernard
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
Dr. Clive A. Meanwell, M.D.
Dr. Clive A. Meanwell, M.D.
Executive Chairman of the Board, Founder
Executive Chairman of the Board, Founder
--
--
Mr. Christopher Whitten Bernard
Mr. Christopher Whitten Bernard
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher J. (Chris) Visioli
Mr. Christopher J. (Chris) Visioli
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARCH Venture Partners
25.53%
Fidelity Management & Research Company LLC
15.00%
Validae Health, L.P
12.15%
Alphabet, Inc.
4.72%
MIC Capital Management UK LLP
4.32%
Other
38.28%
Shareholders
Shareholders
Proportion
ARCH Venture Partners
25.53%
Fidelity Management & Research Company LLC
15.00%
Validae Health, L.P
12.15%
Alphabet, Inc.
4.72%
MIC Capital Management UK LLP
4.32%
Other
38.28%
Shareholder Types
Shareholders
Proportion
Venture Capital
36.77%
Investment Advisor
26.84%
Corporation
12.15%
Investment Advisor/Hedge Fund
9.96%
Hedge Fund
3.89%
Individual Investor
0.91%
Research Firm
0.12%
Bank and Trust
0.06%
Other
9.30%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
133
95.51M
90.92%
+74.51M
2025Q1
104
95.08M
90.50%
+81.16M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARCH Venture Partners
26.82M
25.53%
+26.82M
--
Feb 03, 2025
Fidelity Management & Research Company LLC
15.17M
14.44%
+4.11M
+37.16%
Mar 31, 2025
Validae Health, L.P
12.77M
12.15%
+12.77M
--
Mar 31, 2025
Alphabet, Inc.
4.96M
4.72%
+4.96M
--
Mar 31, 2025
MIC Capital Management UK LLP
4.54M
4.32%
+4.54M
--
Mar 31, 2025
VR Adviser, LLC
3.75M
3.57%
+3.75M
--
Mar 31, 2025
Wellington Management Company, LLP
2.40M
2.29%
+544.29K
+29.30%
Mar 31, 2025
Janus Henderson Investors
2.91M
2.77%
+2.91M
--
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
2.89M
2.75%
+2.89M
--
Mar 31, 2025
Alpha Wave Global, LP
2.38M
2.27%
+2.38M
--
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
Roundhill GLP-1 & Weight Loss ETF
4.05%
ALPS Medical Breakthroughs ETF
2.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.74%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
ProShares Hedge Replication ETF
0.02%
Global X Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
View more
Roundhill GLP-1 & Weight Loss ETF
Proportion4.05%
ALPS Medical Breakthroughs ETF
Proportion2.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.74%
SPDR S&P Biotech ETF
Proportion0.16%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
